Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01236105 | Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject | PHASE1 | COMPLETED | 21 | — | — | Oct 1, 2010 | Dec 1, 2010 | Dec 22, 2011 | 1 | United Kingdom |
AUC from time 0, extrapolated to infinity, estimated for both LY2624803 and the metabolite LSN2797276.
Cmax estimated for both LY2624803 and the metabolite LSN2797276.
| Arm | Type | Description |
|---|---|---|
| 6 mg LY2624803 Alone Morning Dosing | EXPERIMENTAL | Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast. |
| 6 mg LY2624803 Morning Dosing + Activated Charcoal | EXPERIMENTAL | Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola. |
| 6 mg LY2624803 Alone Evening Dosing | EXPERIMENTAL | Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast. |
| Name | Type | Description |
|---|---|---|
| LY2624803 | DRUG | Administered orally (po), once. |
| Activated Charcoal | OTHER | Administered po |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination. * Male subjects with female partners of child-bearing potential and female subjects of child-bearing potential, agree to use 2 reliable methods of contraception from the time of th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 3 | PHASE3 | Tasimelteon |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan , Astra-Zeneca |
| Unity Health Toronto | UBX | 1 | PHASE2 | Lemborexant |
| ResMed Inc. | RMD | 1 | NA | Undisclosed |
| IQVIA Holdings Inc | IQV | 1 | — | Daridorexant, Non-orexin receptor antagonist medications for insomnia |